Edwards Lifesciences faces stock risk ahead of trial results says Stifel

Edwards Lifesciences may face greater downside risk than upside potential ahead of the TCT 2026 medical meeting, according to Stifel's analysis of physician feedback collected prior to the PROGRESS trial data release on November 2. The PROGRESS trial aims to determine if transcatheter aortic valve replacement offers benefits for patients with moderate aortic stenosis.

Stifel consulted four senior interventional cardiologists who expect the trial to meet its composite primary endpoint, which tracks death or heart-failure events within two years. The doctors believe the trial will likely achieve this through the heart-failure aspect rather than mortality benefits, as the two-year follow-up period may be too brief to observe mortality gains in the transcatheter aortic valve replacement (TAVR) group.

Most investors and physicians anticipate positive data from PROGRESS, suggesting that expectations may already be incorporated into current investment outlooks. Historical data indicates limited stock gains when positive trial expectations are pre-existing, even when the long-term implications prove favorable. For instance, Boston Scientific's shares dropped 9% the day after the CHAMPION-AF trial met primary endpoints in March 2026, as the medical community recognized potential complications in the positive data narrative.

At TCT 2025, Edwards shares increased by 6% post the release of the seven-year PARTNER 3 data, while positive EARLY TAVR results contributed to minimal immediate stock movement at TCT 2024. The physicians highlighted that a positive PROGRESS outcome could potentially lead to earlier referrals and more conservative treatment approaches in centers managing borderline patients.

Two of the physicians expressed doubts about whether the trial's definition of moderate aortic stenosis truly matches their clinical judgment. The TCT 2026 medical meeting will take place from October 31 to November 3 in San Diego.